PathAI Stock
PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.
Sign up today and learn more about PathAI Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PathAI Stock
PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
Investors
General Atlantic
AppDynamics, Toutiao, Chime, Wish, Avant, Articulate, Bolt Financial, Automation Anywhere, Coalition, Blend
General Catalyst Partners
Snap, Jet, Stripe, Anduril Industries, Devoted Health, Lacework, Relativity Space, Oscar Health, Circle, Hopin
Funding History
| December 2016 | $4.2M |
|---|---|
| November 2017 | $11.0M |
| April 2019 | $60.0M |
| November 2019 | $15.0M |
Management
Co-founder & CEO
Andrew Beck
Co-founder & CTO
Aditya Khosla
Senior Software Engineer
Nicholas Vecellio
Independent Product Management Consultant
Gopal Shenoy
Press
news - Jul, 28 2023
The Crunchbase Tech Layoffs Trackerbizjournals - Jul, 21 2023
PathAI, one of Massachusetts' largest healthtech companies, cuts 87 jobsprnewswire - Jun, 14 2023
PathAI Announces New Executive Appointment to Drive Commercial Growth of Biopharma Partnerships, Lab Capabilities, and Clinical Innovationbiospace - Apr, 12 2023
Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applicationsprnewswire - Mar, 31 2023
PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trialbusinesswire - Feb, 16 2023
PathAI Announces Two New Executives to Expand Regulatory Expertise and Precision Oncology Commercial Strategybiospace - Jul, 14 2022
PathAI Appoints Brandon Eldredge as Chief Financial Officerfiercebiotech - Jun, 22 2022
PathAI co-founder Khosla carves a new path as CTO of Iterative Scopesventurebeat - May, 2 2022
Cleveland Clinic and PathAI partner to identify diseases and offer treatmentbiospace - Apr, 6 2022
PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Developmentfiercehealthcare - Mar, 14 2022
Cleveland Clinic teams up with PathAI to develop new pathology diagnosticsmobihealthnews - Mar, 11 2022
PathAI, Cleveland Clinic partner to use AI-enabled pathology for researchdeepai - Nov, 13 2021
PathAI Composite PD-L1 and AI-powered CD8+ Topology Biomarker May Improve ...aithority - Oct, 23 2021
PathAI Welcomes Two New Executives as it Strengthens its Biopharma Business Leadership Teambiospace - Oct, 19 2021
PathAI Announces Strategic Partnership with Roche to Enable Development and Distribution of Digital Pathology Diagnosticsfiercebiotech - Oct, 19 2021
Roche welcomes PathAI into its open digital pathology initiativevator - Jul, 29 2021
Path AI buys Poplar Healthcare; Happify launches PDTx for mental health; Delta COVID variant updatefiercebiotech - Jul, 27 2021
PathAI branches into clinical lab services with acquisition of Poplar Healthcareow - Jul, 27 2021
PathAI acquires part of Poplar pathology labneurons - Jun, 25 2021
PathAI to Present Machine Learning-Based Drug Development Tool For Assessment of …startuparound - Jun, 4 2021
The 12 Largest US Tech Startup Funding Rounds of May 2021bizjournals - May, 19 2021
Fenway AI startup raises its largest VC round ever at $165Mnews - Mar, 23 2021
Strategy Session: KdT Ventures Focuses Second Fund On Frontier Scienceprweb - Mar, 8 2021
PathAI and Labcorp Broaden Strategic Collaboration to Accelerate Use of AI-Powered Pathologynews - Oct, 26 2020
PathAI Chooses Digital Realty's PlatformDIGITAL® to Deploy AI Workloadsprweb - May, 30 2020
PathAI Demonstrates the Potential of AI-based Characterization of the Tumor Microenvironment at ASCOprweb - Nov, 8 2019
PathAI and Gilead Show AI-Powered Pathology Research Models Accurately Interpret Liver Histology in Patients with NASH at AASLD 2019finsmes - Nov, 4 2019
PathAI Receives Investment from Merck and Bristol-Myers Squibb; Completes $75M Series Bnanalyze - Nov, 2 2019
7 AI Cancer Diagnostics Startups Digitizing HealthcareEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
